** Protara Therapeutics TARA.O shares down 9.5% to $6.04 in extended trading on planned equity raise. Shares on Mon closed up 12.9% at $6.67
** Cancer and rare-disease treatment firm announces offering of stock and pre-funded warrants; deal size not disclosed
** It intends to use net offering proceeds to fund clinical development of TARA-002, and development of other clinical programs
** TARA shares on Thurs finished session up 70% at $6.02 after co said TARA-002 helped remove all signs of cancer in 72% of patients at six months of treatment for non-muscle invasive bladder cancer (NMIBC) in mid-stage study
** Co has ~20.6 mln shares outstanding for ~$137 mln market cap
** TD Cowen, Cantor, LifeSci Capital, Oppenheimer and Scotiabank jt bookrunners for offering
** TARA shares ended 2023 at $1.88
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。